Novartis, Bristol To Share Zelmac; Novartis Opts For Partnership, Not Merger
Executive Summary
Novartis' agreement with Bristol Myers-Squibb to co-promote the irritable bowel syndrome treatment Zelmac (tegaserod) accomplishes one objective of the Swiss company's attempts to grow via a merger in the U.S.
You may also be interested in...
Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.
Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.
Novartis U.S. Rx Marketing Head Schofield Joins From Pharmacia
Novartis' efforts to reinvigorate its U.S. pharmaceuticals business in 2001 will be led by former Pharmacia VP-U.S. Sales Greg Schofield.